For the GEPIA-derived cohort, the expression levels of S100A11, S100A16, and S100B in low-grade glioma (LGG) and GBM samples increased compared with those in noncarcinoma samples, while S10013 in LGG tissue was upregulated in normal tissues (Figure 8). This evidence concerns the gene S100A16 and central nervous system cancer.